x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012842
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala933 of human SMARCAL1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SMARCAL1 |
| UniProt No. | Q9NZC9 |
| Gene ID | 50485 |
| Gene Description | SMARCAL1 was first identified as a ubiquitously expressed member of the SNF2 family with homology to the E. coli protein HepA. Mutations in the gene encoding SMARCAL1 were subsequently shown to be the cause of Schimke immuno-osseous dysplasia, an autosomal recessive disorder characterized by phenotypes in multiple systems, including spondyloepiphyseal dysplasia, renal dysfunction, immunodeficiency, and impaired neurological function. Researchers have also associated SMARCAL1 deficiency with predisposition to non-Hodgkin's lymphoma. The array of phenotypes associated with SMARCAL1 is likely due to its role as an annealing helicase in the DNA damage response. During DNA replication stress, SMARCAL1 is phosphorylated by DNA repair kinases. SMARCAL1 deficiency sensitizes cells to replication stress agents, and appears to increase the frequency of replication fork breakdown. SMARCAL1 is also required for efficient DNA double strand break repair via the nonhomologous end joining DNA repair pathway. Researchers have suggested that inhibitors targeting SMARCAL1 may be effective in sensitizing cancer cells to chemotherapeutic agents. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
